Title |
Schistosomiasis vaccines: where do we stand?
|
---|---|
Published in |
Parasites & Vectors, September 2016
|
DOI | 10.1186/s13071-016-1799-4 |
Pubmed ID | |
Authors |
Biniam Mathewos Tebeje, Marina Harvie, Hong You, Alex Loukas, Donald P. McManus |
Abstract |
Schistosomiasis, caused mainly by S. mansoni, S. haematobium and S. japonicum, continues to be a serious tropical disease and public health problem resulting in an unacceptably high level of morbidity in countries where it is endemic. Praziquantel, the only drug currently available for treatment, is unable to kill developing schistosomes, it does not prevent re-infection and its continued extensive use may result in the future emergence of drug-resistant parasites. This scenario provides impetus for the development and deployment of anti-schistosome vaccines to be used as part of an integrated approach for the prevention, control and eventual elimination of schistosomiasis. This review considers the present status of candidate vaccines for schistosomiasis, and provides some insight on future vaccine discovery and design. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | <1% |
Unknown | 228 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 42 | 18% |
Student > Bachelor | 36 | 16% |
Student > Ph. D. Student | 34 | 15% |
Student > Postgraduate | 13 | 6% |
Student > Doctoral Student | 11 | 5% |
Other | 36 | 16% |
Unknown | 57 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 37 | 16% |
Agricultural and Biological Sciences | 29 | 13% |
Medicine and Dentistry | 27 | 12% |
Immunology and Microbiology | 26 | 11% |
Chemistry | 11 | 5% |
Other | 32 | 14% |
Unknown | 67 | 29% |